RPRX
Royalty Pharma plc
NASDAQ · Healthcare · Biotechnology · US
$63.96
+0.13%Forward multiples
Based on analyst estimates
- P/E forward
- 13.90x
- P/E 2026E
- 12.02x
- P/E 2027E
- 11.17x
- P/E 2028E
- 9.90x
- P/S forward
- 8.27x
Trailing multiples
Trailing twelve months
- P/E TTM
- 26.54x
- PEG TTM
- 0.29x
- Price / book
- 4.17x
- Price / sales
- 11.23x
- Price / cash flow
- 9.57x
Enterprise value
- Enterprise value
- $39.6B
- EV / sales
- 15.60x
- EV / EBITDA
- 23.05x
- EV / EBIT
- 25.02x
- Market cap
- $28.5B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026